EAM
Erste Asset Management Portfolio holdings
AUM
$11.9B
1-Year Return
22.95%
This Quarter Return
+22.83%
1 Year Return
+22.95%
3 Year Return
+112.82%
5 Year Return
+205.55%
10 Year Return
–
AUM
$3.61B
AUM Growth
+$682M
(+23%)
Cap. Flow
+$165M
Cap. Flow
% of AUM
4.58%
Top 10 Holdings %
Top 10 Hldgs %
17.47%
Holding
954
New
83
Increased
179
Reduced
131
Closed
34
Top Buys
| 1 |
Biogen
BIIB
|
+$35.3M |
| 2 |
Signet Jewelers
SIG
|
+$13.5M |
| 3 |
Microsoft
MSFT
|
+$12.7M |
| 4 |
Silicon Motion
SIMO
|
+$11M |
| 5 |
TJX Companies
TJX
|
+$11M |
Top Sells
| 1 |
Darden Restaurants
DRI
|
+$27.2M |
| 2 |
Tapestry
TPR
|
+$15.7M |
| 3 |
Ameriprise Financial
AMP
|
+$12.6M |
| 4 |
Abbott
ABT
|
+$9.4M |
| 5 |
Denali Therapeutics
DNLI
|
+$9.37M |
Sector Composition
| 1 | Technology | 27.61% |
| 2 | Healthcare | 21.59% |
| 3 | Consumer Discretionary | 15.04% |
| 4 | Industrials | 8.92% |
| 5 | Financials | 8.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Y-mAbs Therapeutics
YMAB
$390M
| $504K | 0.01% |
+10,000
| New | +$504K |
|
377
Steel Dynamics
STLD
$19.8B
| $498K | 0.01% |
+13,700
| New | +$498K |
|
378
Veeva Systems
VEEV
$46.3B
| $496K | 0.01% |
1,800
| – | – |
|
379
Scholar Rock
SRRK
$3.04B
| $490K | 0.01% |
+10,300
| New | +$490K |
|
|
VIE
380
DELISTED
Viela Bio, Inc. Common Stock
VIE
| $487K | 0.01% |
+13,400
| New | +$487K |
|
381
Replimune Group
REPL
$454M
| $486K | 0.01% |
+11,900
| New | +$486K |
|
382
American Express
AXP
$226B
| $484K | 0.01% |
4,100
-2,255
| -35% | -$266K |
|
383
Freeport-McMoran
FCX
$67B
| $478K | 0.01% |
19,000
+14,400
| +313% | +$362K |
|
384
Genmab
GMAB
$16.9B
| $477K | 0.01% |
+12,000
| New | +$477K |
|
385
Pembina Pipeline
PBA
$22.1B
| $465K | 0.01% |
+19,400
| New | +$465K |
|
386
Nkarta
NKTX
$151M
| $462K | 0.01% |
+7,200
| New | +$462K |
|
387
Atara Biotherapeutics
ATRA
$85.5M
| $449K | 0.01% |
+880
| New | +$449K |
|
388
FMC
FMC
$4.73B
| $440K | 0.01% |
3,854
+2,052
| +114% | +$234K |
|
389
B2Gold
BTG
$5.6B
| $436K | 0.01% |
+76,629
| New | +$436K |
|
|
BKI
390
DELISTED
Black Knight, Inc. Common Stock
BKI
| $425K | 0.01% |
4,818
-9,843
| -67% | -$869K |
|
391
Ligand Pharmaceuticals
LGND
$3.23B
| $425K | 0.01% |
6,893
-4,649
| -40% | -$287K |
|
392
Keros Therapeutics
KROS
$628M
| $425K | 0.01% |
+5,700
| New | +$425K |
|
393
Aurinia Pharmaceuticals
AUPH
$1.62B
| $418K | 0.01% |
30,000
-61,000
| -67% | -$850K |
|
394
MacroGenics
MGNX
$111M
| $411K | 0.01% |
+18,000
| New | +$411K |
|
395
Brown & Brown
BRO
$31.5B
| $410K | 0.01% |
+8,900
| New | +$410K |
|
396
Pfizer
PFE
$140B
| $409K | 0.01% |
11,083
-101,441
| -90% | -$3.75M |
|
397
Ball Corp
BALL
$13.9B
| $406K | 0.01% |
+4,400
| New | +$406K |
|
398
Reinsurance Group of America
RGA
$12.7B
| $403K | 0.01% |
3,500
-2,000
| -36% | -$230K |
|
399
Vaxcyte
PCVX
$4.21B
| $398K | 0.01% |
+14,200
| New | +$398K |
|
|
TBIO
400
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $390K | 0.01% |
+20,000
| New | +$390K |
|